Acute Lymphoblastic Leukemia (ALL)
Malignant Proliferation of Lymphoid Progenitor Cells
Primary risk age: 2 to 5 Years (Peak incidence, though occurs throughout childhood; most common pediatric cancer)
- Urgency
- Emergency
- Typical age
- 2 to 5 Years (Peak incidence, though occurs throughout childhood; most common pediatric cancer)
- Body system
- Oncological System
Typical course: The total duration of chemotherapy treatment is typically 2 to 2.5 years; recovery of normal bone marrow function occurs within months of completing therapy.
Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13
1. Summary & Pathophysiology
Malignant Proliferation of Lymphoid Progenitor Cells
Pathophysiology (Development Path)
Malignant transformation of a lymphoid progenitor cell (typically a B-cell precursor) leads to uncontrolled clonal expansion. These immature lymphoblasts accumulate in the bone marrow, crowding out normal hematopoiesis. This results in pancytopenia (anemia, thrombocytopenia, neutropenia) and infiltration of external organs (spleen, liver, lymph nodes, CNS).
Primary Causes & Etiology
Somatically acquired genetic mutations in lymphoid progenitor cells, altering cell division and maturation; associated with syndromes like Down syndrome.
2. Symptom Continuum
- Early Onset Signs
Vague, flu-like symptoms including persistent fatigue, progressive pallor, loss of appetite, and a low-grade fever.
- Progressive Phase
Easy bruising, petechiae, recurrent epistaxis, bone pain (often causing a limp or refusal to walk, especially at night), and generalized painless lymphadenopathy (swollen lymph nodes in neck, armpits, groin).
- Severe Indicators
High fever, severe infections (due to neutropenia), hepatosplenomegaly causing abdominal distension, testicular swelling, and signs of increased intracranial pressure (headache, vomiting), indicating CNS involvement.
3. Clinical Verification
Complete blood count showing anemia, thrombocytopenia, and presence of lymphoblasts. Confirmed by a Bone Marrow Aspiration and biopsy showing $ge 20%$ lymphoblasts, with immunophenotyping (flow cytometry) to determine lineage.
4. Care & Elements Plan
Primary Care Treatment Plan
Standardized multi-agent chemotherapy protocols divided into phases: Induction (to achieve remission), Consolidation, and Maintenance therapy. CNS prophylaxis with intrathecal chemotherapy is mandatory. Supportive care with transfusions and antibiotics.
Home Support Elements
This condition requires immediate specialist oncology hospitalization. Post-discharge home care focuses on strict hygiene to prevent infection, avoiding sick contacts, managing chemotherapy side effects, and monitoring for fever.
Generic Active Ingredients (No Brands)
- Vincristine sulfate or Methotrexate (generic chemotherapy active ingredients)
- Prednisone or Dexamethasone (corticosteroid active ingredients used in leukemia protocols)
- Mercaptopurine (active maintenance chemotherapy).
Lists active elements only. Never administer self-designed therapies.
5. Doctor Critical Lines
Critical Thresholds: When to See a Doctor
Any child presenting with unexplained bruising, bone pain that wakes them at night, progressive pallor, or a fever that does not resolve requires immediate pediatric evaluation.
6. Vaccine & Prevention
Routine Prophylaxis (Prevention)
No preventative measures exist, as the genetic mutations are somatic and randomly acquired.
Immunization Context
Avoid all live viral vaccines (MMR, Varicella, Rotavirus) while the child is undergoing immunosuppressive chemotherapy; household contacts should be fully immunized.
7. Timelines & Outlook
Active Timeline
The total duration of chemotherapy treatment is typically 2 to 2.5 years; recovery of normal bone marrow function occurs within months of completing therapy.
Expected Prognosis
Excellent. The 5-year survival rate for pediatric B-cell ALL exceeds 90% with modern risk-directed chemotherapy protocols.
Potential Untreated Complications
Tumor lysis syndrome, febrile neutropenia, severe infections, bleeding, chemotherapy-induced toxicity (cardiotoxicity, neuropathy), and secondary malignancies.
